Merck (MRK) Tops Quarterly Sales Forecasts as Keytruda Drives Growth

Why It Matters

The beat underscores Merck’s resilience in oncology, with Keytruda cementing its revenue engine, while the raised 2026 guidance signals confidence in its pipeline and growth prospects. Investors will watch how the one‑time acquisition charge impacts future profitability.

Key Takeaways

• Q1 revenue hit $16.3B, beating $15.8B estimate.
• Keytruda sales rose 12% to $8B, outpacing $7.6B consensus.
• One‑time $3.62/share Cidara acquisition charge drove net loss.
• Winrevair revenue jumped 88% to $525M, surpassing forecasts.
• 2026 sales outlook lifted to $65.8‑$67B, EPS forecast $5.04‑$5.16.

Pulse Analysis

Merck’s first‑quarter performance highlights the enduring strength of its oncology franchise. Keytruda, the company’s flagship PD‑1 inhibitor, not only delivered a 12% sales lift to $8 billion but also helped the group exceed revenue expectations despite a modest overall growth rate. In a market where many large‑cap pharma peers are grappling with pricing pressures and generic erosion, Merck’s ability to grow a single product at double‑digit rates reinforces its position as a leading immuno‑oncology player and provides a buffer for investors against broader sector volatility.

The quarter’s headline numbers were tempered by a $3.62‑per‑share, one‑time charge tied to the Cidara Therapeutics acquisition, which pushed Merck into a net loss on a GAAP basis. While the charge is non‑recurring, it underscores the company’s strategic push into next‑generation infectious‑disease therapies, a move that could diversify revenue streams beyond oncology. Meanwhile, ancillary products showed mixed results: Winrevair surged 88% to $525 million, reflecting strong demand in its niche, whereas Gardasil sales slipped 19% to $1.07 billion as demand waned in China and Japan, illustrating regional sensitivities in vaccine markets.

Looking ahead, Merck’s revised 2026 guidance—$65.8‑$67 billion in sales and $5.04‑$5.16 earnings per share—signals confidence in its pipeline, which includes several late‑stage candidates poised to become future blockbusters. The guidance also places Merck ahead of many peers that have trimmed forecasts amid macro‑economic headwinds. Investors will likely focus on how effectively the company integrates Cidara’s assets, sustains Keytruda’s growth trajectory, and navigates competitive pressures from emerging immunotherapies, all of which will shape its long‑term valuation.